{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:52:19Z","timestamp":1793303539640,"version":"4.5.0"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["19920"],"award-info":[{"award-number":["19920"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21147"],"award-info":[{"award-number":["21147"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC-2020"],"award-info":[{"award-number":["RC-2020"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["800924"],"award-info":[{"award-number":["800924"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,12,17]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Toll-like receptors (TLRs) are pattern-recognition sensors mainly expressed in innate immune cells that directly recognize conserved pathogen structures (pathogen-associated molecular patterns-PAMPs). Natural killer (NK) cells have been described to express different endosomal TLRs triggered by RNA and DNA sequences derived from both viruses and bacteria. This study was addressed to establish which endosomal TLR could directly mediate NK activation and function after proper stimuli. It was also important to establish the most suitable TLR agonist to be used as adjuvant in tumor vaccines or in combined cancer immunotherapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We assessed endosomal TLR expression in total NK cells by using RT-qPCR and western blotting technique. In some experiments, we purified CD56<jats:sup>bright<\/jats:sup>CD16<jats:sup>\u2212<\/jats:sup> and CD56<jats:sup>dim<\/jats:sup>CD16<jats:sup>+<\/jats:sup> cells subsets by using NK Cell Isolation Kit Activation marker, cytokine production, CD107a expression and cytotoxicity assay were evaluated by flow cytometry. Cytokine release was quantified by ELISA. NK cells obtained from ovarian ascites underwent the same analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Although the four endosomal TLRs (TLR3, TLR7\/8, and TLR9) were uniformly expressed on CD56<jats:sup>bright<\/jats:sup>CD16<jats:sup>\u2212<\/jats:sup> and CD56<jats:sup>dim<\/jats:sup>CD16<jats:sup>+<\/jats:sup> cell subsets, the TLR7\/8 (R848), TLR3 (polyinosinic-polycytidylic acid, Poly I:C) and TLR9 (ODN2395) ligands promoted NK-cell function only in the presence of suboptimal doses of cytokines, including interleukin (IL)-2, IL-12, IL-15, and IL-18, produced <jats:italic>in vivo<\/jats:italic> by other environmental cells. We showed that R848 rather than TLR3 and TLR9 agonists primarily activated CD56<jats:sup>bright<\/jats:sup>CD16<jats:sup>\u2212<\/jats:sup> NK cells by increasing their proliferation, cytokine production and cytotoxic activity. Moreover, we demonstrated that R848, which usually triggers TLR7 and TLR8 on dendritic cells, macrophages and neutrophils cells, activated CD56<jats:sup>bright<\/jats:sup>CD16<jats:sup>\u2212<\/jats:sup> NK-cell subset only via TLR8. Indeed, specific TLR8 but not TLR7 agonists increased cytokine production and cytotoxic activity of CD56<jats:sup>bright<\/jats:sup>CD16<jats:sup>\u2212<\/jats:sup> NK cells. Importantly, these activities were also observed in peritoneal NK cells from patients with metastatic ovarian carcinoma, prevalently belonging to the CD56<jats:sup>bright<\/jats:sup>CD16<jats:sup>\u2212<\/jats:sup> subset.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These data highlight the potential value of TLR8 in NK cells as a new target for immunotherapy in patients with cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003385","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T10:11:44Z","timestamp":1643364704000},"page":"e003385","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":45,"title":["Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56<sup>bright<\/sup>CD16<sup>\u2212<\/sup> subset"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1243-3757","authenticated-orcid":false,"given":"Irene","family":"Veneziani","sequence":"first","affiliation":[{"name":"Department of Immunology, Bambino Gesu Pediatric Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Alicata","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bambino Gesu Pediatric Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2308-9215","authenticated-orcid":false,"given":"Andrea","family":"Pelosi","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bambino Gesu Pediatric Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Landolina","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bambino Gesu Pediatric Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biancamaria","family":"Ricci","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bambino Gesu Pediatric Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"D'Oria","sequence":"additional","affiliation":[{"name":"Confocal Microscopy Core Facility, Bambino Gesu Pediatric Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[{"name":"Department of Woman's Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"},{"name":"Department of Life Sciences and Public Health, Universit\u00e0 Cattolica del Sacro Cuore, Campus di Roma, Roma, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[{"name":"Department of Woman's Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy"},{"name":"Department of Life Sciences and Public Health, Universit\u00e0 Cattolica del Sacro Cuore, Campus di Roma, Roma, Lazio, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moretta","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bambino Gesu Pediatric Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Maggi","sequence":"additional","affiliation":[{"name":"Department of Immunology, Bambino Gesu Pediatric Hospital, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"2025100309203468000_10.1.e003385.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141126"},{"key":"2025100309203468000_10.1.e003385.2","doi-asserted-by":"publisher","DOI":"10.1038\/35099560"},{"key":"2025100309203468000_10.1.e003385.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5396.2085"},{"key":"2025100309203468000_10.1.e003385.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2201"},{"key":"2025100309203468000_10.1.e003385.5","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.02297","article-title":"Human NK cells and herpesviruses: mechanisms of recognition, response and adaptation","volume":"10","author":"Della Chiesa","year":"2019","journal-title":"Front Microbiol"},{"key":"2025100309203468000_10.1.e003385.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2003.10.012"},{"key":"2025100309203468000_10.1.e003385.7","doi-asserted-by":"publisher","DOI":"10.2174\/092986712800099857"},{"key":"2025100309203468000_10.1.e003385.8","doi-asserted-by":"publisher","DOI":"10.1038\/7403"},{"key":"2025100309203468000_10.1.e003385.9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.197"},{"key":"2025100309203468000_10.1.e003385.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2876"},{"key":"2025100309203468000_10.1.e003385.11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.3.1455"},{"key":"2025100309203468000_10.1.e003385.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1443"},{"key":"2025100309203468000_10.1.e003385.13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.cji.0000211304.60126.8f","article-title":"Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma","volume":"29","author":"Link","year":"2006","journal-title":"J Immunother"},{"key":"2025100309203468000_10.1.e003385.14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdw608","article-title":"A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer","volume":"28","author":"Belani","year":"2017","journal-title":"Annals of Oncology"},{"key":"2025100309203468000_10.1.e003385.15","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/hed.24704","article-title":"Induction of tumor regression by intratumoral sting agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model","volume":"39","author":"Gadkaree","year":"2017","journal-title":"Head Neck"},{"key":"2025100309203468000_10.1.e003385.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-630335"},{"key":"2025100309203468000_10.1.e003385.17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0313"},{"key":"2025100309203468000_10.1.e003385.18","doi-asserted-by":"crossref","first-page":"712377","DOI":"10.3389\/fcell.2021.712377","article-title":"Lamin A\/C mechanosensor drives tumor cell aggressiveness and adhesion on substrates with tissue-specific elasticity","volume":"9","author":"Urciuoli","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025100309203468000_10.1.e003385.19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00957","article-title":"Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing","volume":"10","author":"Ingegnere","year":"2019","journal-title":"Front Immunol"},{"key":"2025100309203468000_10.1.e003385.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403744101"},{"key":"2025100309203468000_10.1.e003385.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2006.08.004"},{"key":"2025100309203468000_10.1.e003385.22","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.3.1636"},{"key":"2025100309203468000_10.1.e003385.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1012356108"},{"key":"2025100309203468000_10.1.e003385.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2820"},{"key":"2025100309203468000_10.1.e003385.25","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxl046"},{"key":"2025100309203468000_10.1.e003385.26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.12.7658"},{"key":"2025100309203468000_10.1.e003385.27","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm105"},{"key":"2025100309203468000_10.1.e003385.28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.727"},{"key":"2025100309203468000_10.1.e003385.29","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535781"},{"key":"2025100309203468000_10.1.e003385.30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M605003200"},{"key":"2025100309203468000_10.1.e003385.31","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/JLB.3MA0520-054R","article-title":"Human neutrophils activated by TLR8 agonists, with or without IFN\u03b3, synthesize and release EBI3, but not IL\u201012, IL\u201027, IL\u201035, or IL\u201039","volume":"108","author":"Cassatella","year":"2020","journal-title":"J Leukoc Biol"},{"key":"2025100309203468000_10.1.e003385.32","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/JLB.MA0818-308R","article-title":"Human neutrophils activated via TLR8 promote Th17 polarization through IL\u201023","volume":"105","author":"Tamassia","year":"2019","journal-title":"J Leukoc Biol"},{"key":"2025100309203468000_10.1.e003385.33","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093620"},{"key":"2025100309203468000_10.1.e003385.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.003"},{"key":"2025100309203468000_10.1.e003385.35","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21321"},{"key":"2025100309203468000_10.1.e003385.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209414109"},{"key":"2025100309203468000_10.1.e003385.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3229"},{"key":"2025100309203468000_10.1.e003385.38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020404","article-title":"Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways","volume":"18","author":"Li","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025100309203468000_10.1.e003385.39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01383"},{"key":"2025100309203468000_10.1.e003385.40","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1021\/acs.molpharmaceut.8b01165","article-title":"Combination of sunitinib and PD-L1 blockade enhances anticancer efficacy of TLR7\/8 Agonist-Based Nanovaccine","volume":"16","author":"Kim","year":"2019","journal-title":"Mol Pharm"},{"key":"2025100309203468000_10.1.e003385.41","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994398","article-title":"Controlling T cell senescence in the tumor microenvironment for tumor immunotherapy","volume":"4","author":"Ye","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025100309203468000_10.1.e003385.42","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/annonc\/mdx049","article-title":"A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study","volume":"28","author":"Monk","year":"2017","journal-title":"Annals of Oncology"},{"key":"2025100309203468000_10.1.e003385.43","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/leu.2014.293","article-title":"The role of TLR8 signaling in acute myeloid leukemia differentiation","volume":"29","author":"Ignatz-Hoover","year":"2015","journal-title":"Leukemia"},{"key":"2025100309203468000_10.1.e003385.44","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0724-8"},{"key":"2025100309203468000_10.1.e003385.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1934"},{"key":"2025100309203468000_10.1.e003385.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.11.002"},{"key":"2025100309203468000_10.1.e003385.47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ctrv.2018.10.012","article-title":"In vivo cancer vaccination: which dendritic cells to target and how?","volume":"71","author":"Chiang","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2025100309203468000_10.1.e003385.48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0334"},{"key":"2025100309203468000_10.1.e003385.49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/17460441.2021.1898369","article-title":"Recent trends in the development of Toll-like receptor 7\/8-targeting therapeutics","volume":"16","author":"Huang","year":"2021","journal-title":"Expert Opin Drug Discov"}],"updated-by":[{"DOI":"10.1136\/jitc-2021-003385corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:20:47Z","timestamp":1759508447000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,28]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/jitc-2021-003385"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003385","relation":{"correction":[{"id-type":"doi","id":"10.1136\/jitc-2021-003385corr1","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}